May 20, 2025, 13:36 | Science

Arndt Vogel: Study on Pembrolizumab and ctDNA in dMMR/MSI-H Tumors

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology…

May 20, 2025, 10:19 | Science

Yüksel Ürün: KEYNOTE-991 Trial Results in mHSPC Treatment

Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared an article on X:…

May 20, 2025, 07:14 | Opinion

Amol Akhade Shared Key Lung Cancer Trials from ASCO 2025

Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared a post on X:…

May 13, 2025, 10:51 | Science

Luis Lara-Mejía: Radiotherapy in 1st Line Metastatic NSCLC

Luis Lara-Mejía, Medical Oncologist Specialized in Thoracic Neoplasms at National Institute of Cancerology, shared an article…

May 1, 2025, 09:14 | Science

Praveen Kumar Marimuthu: Pembrolizumab in previously treated patients with Advanced Clear Cell Gynecological Cancer

Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital, shared an…

Apr 27, 2025, 04:42 | Cancer Types

Triple-Negative Breast Cancer: Symptoms ,Causes, Types, Diagnosis and Treatment

Triple-negative breast cancer (TNBC) is a less common but more aggressive type of breast cancer…

Apr 23, 2025, 10:12 | Blog

Matthew Kurian: From ASCENT-04 may reshape frontline therapy for mTNBC

Matthew Kurian, Assistant professor of medicine at the University of Kentucky College of Medicine, shared a…

Apr 16, 2025, 15:03 | Insight

Richard Sullivan: The 2025 model lists of essential medicines for cancer

Richard Sullivan, Director of the Institute of Cancer Policy and Co-Director of the Centre for…

Apr 13, 2025, 18:24 | Blog

Akhil Santhosh: First-Line Adagrasib and Pembrolizumab for Metastatic NSCLC

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post…

Apr 6, 2025, 10:38 | Science

Seyed Alireza Javadinia: Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous SCC

Seyed Alireza Javadinia, Vice President for Research and Technology at Sabzevar University of Medical Sciences,…

Apr 4, 2025, 09:15 | Blog

Tian Zhang: Best practices for second line treatment in Metastatic Urothelial Carcinoma

Tian Zhang, Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center, shared…

Apr 3, 2025, 08:53 | Drugs

Tian Zhang and Petros Grivas discussed best practices for Metastatic Urothelial Carcinoma Therapy

Tian Zhang, Associate Director of Clinical Research at Simmons Comprehensive Cancer Center and Director of…

Apr 1, 2025, 09:47 | Science

Giulia Claire Giudice: Strategies for RCC patients progressing on ICIs

Giulia Claire Giudice, Medical Doctor at University Hospital of Parma, shared an article on X: "Newly…

Mar 31, 2025, 20:43 | Blog

Akhil Santhosh: Pembrolizumab and lenvatinib show promise in mesothelioma treatment

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post…

Mar 29, 2025, 21:34 | Insight

Elvina Almuradova: Pembrolizumab plus CRT as the New Standard in Locally Advanced Cervical Cancer

Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a…

Mar 28, 2025, 14:31 | Blog

Jordi Remon: Adagrasib and pembrolizumab show impressive mPFS in KRAS G12C mutant NSCLC

Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X: "Adagrasib 400 mg…

Mar 28, 2025, 14:09 | Oncolibrary

Ocular Side Effects Of Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) are a type of immunotherapy that enhances the body’s immune response…

Mar 28, 2025, 13:29 | Blog

Elvina Almuradova: Second interim analysis confirms the benefit from addition of Pembrolizumab to CRT

Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a…

Mar 27, 2025, 14:45 | Blog

SC pembrolizumab demonstrated noninferiority compared with IV pembrolizumab in the phase III MK-3475A-D77 trial - ESMO

ESMO - European Society for Medical Oncology shared a post on LinkedIn: "As presented at…

Mar 27, 2025, 14:20 | Blog

New treatments for advanced/metastatic RAS-mutated NSCLC presented at ELCC25 - ESMO

ESMO - European Society for Medical Oncology shared a post on LinkedIn: "Clinical Trials presented…

Mar 24, 2025, 18:22 | Insight

Tanja Obradovic: A novel mechanism for first-line melanoma patients is going to be explored by Eikon Therapeutics

Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn: "Since…

Mar 13, 2025, 08:31 | Blog

Tanja Obradovic: Turmoil within the Biotech sector continues as financing remains a challenge

Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on…

Mar 11, 2025, 14:12 | Science

Nieves Martinez Lago: PEM in MSI and dMMR advanced solid tumors

Nieves Martinez Lago, Medical Oncologist at University Hospital Complex of Ferrol, shared an article by…

Mar 11, 2025, 13:12 | Science

Patrick Forde: PD-1 VEGF bispecific doubles PFS in 1st line advanced NSCLC

Patrick Forde, Professor at Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive…

Mar 2, 2025, 14:36 | Insight

Maite Bourlon: How to treat metastastic urothelial carcinoma after 1st line EV and Pembrolizumab

Maite Bourlon, Associate Professor and Head of the Urologic Oncology Clinic at the National Institute…

Feb 27, 2025, 10:06 | Drugs

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Feb 27, 2025, 10:03 | Blog

Tanja Obradovic: New option of immunotherapy for HNSCC is on the horizon

Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on…

Feb 17, 2025, 08:07 | Science

Marco Donia: Personalized Cancer Vaccines in Renal Cell Carcinoma - Phase I Study

Marco Donia, Associate Professor in Clinical Oncology at the University of Copenhagen, shared an article…

Jan 29, 2025, 18:07 | Blog

The addition of pembrolizumab to neoadjuvant chemotherapy in the phase III KEYNOTE-756 - European Society for Medical Oncology

ESMO - European Society for Medical Oncology shared a post on LinkedIn: "The addition of…

Jan 26, 2025, 21:58 | Science

Nikolas Naleid: Excited to share our systematic review on pembrolizumab safety in GI cancers

Nikolas Naleid, Internal Medicine resident at Case Western Reserve/UH Cleveland Medical Center, shared a recent…

Jan 26, 2025, 08:44 | Science

Paolo Cotzia: The safety and effectiveness of combining two intratumoral immunotherapies for treating high-risk DCIS

Paolo Cotzia, Medical Director of Molecular Pathology and Head of Molecular Excellence at Sonic Healthcare…

Jan 25, 2025, 03:21 | Insight

Senthil Kumar discusses the KEYNOTE-590 study on advanced esophageal cancer

Senthil Kumar, Medical Oncologist at Red Hills Chennai, shared a post on X about a…

Jan 23, 2025, 13:56 | Science

2 Neoadjuvant chemo-IO trials for high-risk ER+ BC

Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared an article by Fatima Cardoso…

Jan 23, 2025, 12:49 | Blog

Paolo Ascierto: Pembrolizumab indication extended for neoadjuvant therapy in melanoma

Paolo Ascierto, Director of Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at RCCS National…

Jan 21, 2025, 15:29 | Science

Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma

Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared an article by Wan-Qin…

Jan 21, 2025, 09:58 | Blog

Kristina Jankovic: Intratumoral Pembrolizumab and mRNA-2752 for High-Risk DCIS

Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, posted the following on X:…

Jan 14, 2025, 06:47 | Insight

Chokri Ben Lamine: Five-year follow-up of KEYNOTE-087

Chokri Ben Lamine, Adult Hematology, Stem Cell Transplantation and Cellular Therapy Assistant Consultant at King…

Jan 4, 2025, 16:32 | Insight

John Simmerling: Amazing molecular animation video on an activated T-cell engaging with a diseased cell

John Simmerling, Chief Science Officer at Biomedical and Healthcare Technology Solutions Group, shared a post…

Jan 3, 2025, 12:45 | Insight

Drew Moghanaki: ‘Some pembrolizumab’ is better than ‘No pembrolizumab’ in patients scheduled for preop chemo

Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA,…

Jan 3, 2025, 12:40 | Insight

Senthil Kumar: First-Line Therapy in RCC, Expanding Choices in a New Era

Senthil Kumar, Medical Oncologist at Red Hills, Chennai, posted on X: “First-Line Therapy in RCC:…

Jan 2, 2025, 16:54 | Insight

Gustavo Viani: Top 10 clinical trials of 2024 that are reshaping how we treat cancer

Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, shared a post on…

Dec 31, 2024, 09:39 | Insight

NFCR joins the nation in mourning the passing of former President James (Jimmy) Carter

National Foundation for Cancer Research (NFCR) shared on LinkedIn: “The National Foundation for Cancer Research…

Dec 27, 2024, 17:02 | Insight

Toni Choueiri: Top 10 GU Bladder/Kidney Cancer Trials for 2024

Toni Choueiri, Director of the Lank Center for GU Oncology at Dana-Farber Cancer Institute, shared…

Dec 25, 2024, 17:37 | Science

Loay Kassem: Study conducted in Egypt shows the cost-effectiveness of KEYNOTE-522 in early TNBC

Loay Kassem, Assistant Professor of clinical oncology at Kasr AlAiny School of Medicine, Cairo University,…

Dec 25, 2024, 16:25 | Blog

Rohit Gosain: Summary of 8 new drugs/indications in Breast Cancer and Gynae Oncology by FDA

Rohit Gosain, Co-Host of Podcast Oncology Brothers, shared a post on LinkedIn: "2024 approvals: Summary of…

Dec 21, 2024, 19:14 | Blog

Pembrolizumab plus chemotherapy with or without bevacizumab for metastatic cervical cancer

James P. Crowley, Professor of Medicine Emeritus at Brown University and serves as a volunteer…

Dec 19, 2024, 01:56 | Science

ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer

An article was published on ESMO Open by A. Vogel and M. Ducreux, titled "ESMO…

Dec 18, 2024, 12:51 | Blog

Bertrand Delsuc: 2 IO agents discontinued at once by $MRK

Bertrand Delsuc, CEO and Founder at Biotellytics, shared a post on X: "Wow, 2 IO…

Dec 16, 2024, 19:28 | Insight

Akhil Santhosh: The key differences between “KEYNOTE 522” and “CAMRELIEF”

Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post…

Dec 16, 2024, 08:33 | Insight

Jarushka Naidoo: KN867 trial shows no EFS benefit for SBRT+Pembro in NSCLC

Jarushka Naidoo, Thoracic Oncologist at the Beaumont Hospital Dublin (Ireland), posted the following on X: “ESMO…

Dec 15, 2024, 11:42 | Science

Five articles suggested by Yüksel Ürün

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey.…

Dec 15, 2024, 10:57 | Blog

Interesting results from the exploratory biomarker analysis of KN-522 study

Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, reshared a post on…

Dec 11, 2024, 19:39 | Blog

Amol Akhade: What Immune Oncology plus chemo combination will u prefer for first line Advanced BTC ?

Amol Akhade shared a post on LinkedIn: "Final Results. What Immune Oncology plus chemo combination…

Dec 10, 2024, 06:28 | Blog

Amol Akhade: Survey for advanced biliary tract cancer treatment

Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…

Dec 9, 2024, 13:18 | Insight

Pembrolizumab vs chemotherapy in MSI-high or MMR-deficient metastatic colorectal cancer

Shivani Modi shared a post on X: "Talk of the town! KEYNOTE-177 trial shows mFU: 73.3…

Dec 8, 2024, 06:30 | Insight

Tom Powles: Cisplatin or Carboplatin-Based Chemotherapy with Pembrolizumab in Advanced Urothelial Cancer

Tom Powles, Director of Barts Cancer Centre, shared a recent article on X: "While EVP…

Dec 7, 2024, 10:43 | Insight

Pembrolizumab vs Chemotherapy in microsatellite instability – high or mismatch repair – deficient metastatic colorectal cancer

Yakup Ergün, Medical Oncologist at Bower Hospital, shared a recent article by T. André on…

Dec 5, 2024, 09:26 | Blog

Pembrolizumab versus chemotherapy in MSI or dMMR metastatic colorectal cancer

Arndt Vogel shared on X: "Pembrolizumab versus chemotherapy in MSI or dMMR mCRC 5-year follow-up from…

Dec 4, 2024, 18:33 | Blog

Rasha Aboelhassan: By the end of the year, everyone is looking for achievements

Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, posted on LinkedIn: "By the end…

Dec 2, 2024, 22:27 | Insight

Survival Outcomes with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a recent article by Peter Schmid…

Nov 25, 2024, 15:26 | Dialogues

ASCO24 Updates: Timothy Burns on Olomorasib and Pembrolizumab in KRAS G12C Tumors

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…

Nov 24, 2024, 13:13 | Insight

Brenda Chahla: Honored to have presented our research on Pembrolizumab in ACC at the 9th International Adrenal Cancer Conference

Brenda Chahla, Postdoctoral Fellow at MD Anderson Cancer Center, shared a post on X: “Very…

Nov 20, 2024, 11:30 | Insight

Flora Xydaki: Biomarkers in Oncology - Transforming Cancer Diagnosis and Treatment

Flora Xydaki, Project Associate at BTHT, shared a post on LinkedIn: "Biomarkers in Oncology: Transforming Cancer…

Nov 13, 2024, 10:37 | Insight

UCLA: Combination approach shows promise for treating rare, aggressive cancers

UCLA research finds that combining immunotherapy with chemotherapy is safe and effective for people with…

Nov 11, 2024, 15:46 | Blog

Tanja Obradovic: New treatment option for patients with low PDL-1 expression in head and neck cancers

Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on…

Nov 10, 2024, 00:39 | Blog

Amol Akhade: Another Negative trial for anti TIGIT drugs - KEYVIBE 008

Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post…

Nov 9, 2024, 20:08 | Blog

Dr. Sara Tolaney Discusses ESMO24 Insights on TroFuse-010 Trial in Advanced Breast Cancer

Dana-Farber’s Breast Oncology Center shared the following on X: “Dr. Sara Tolaney discussed ESMO24 Insights…

Nov 3, 2024, 09:22 | Blog

María Natalia Gandur Quiroga: Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma

María Natalia Gandur Quiroga posted on X: "AMBASSADOR Study: Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma…

Oct 31, 2024, 09:03 | Insight

Jarushka Naidoo: Maintenance Pembrolizumab with or without Olaparib for Advanced Squamous NSCLC

Jarushka Naidoo, Thoracic Oncologist at the Beaumont Hospital Dublin, shared a post on X about…

Oct 30, 2024, 12:41 | Insight

Sahar Barjesteh van Waalwijk van Doorn-Khosrovani: Debates on weight-based dosing of pembrolizumab

Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Podcast Host of De Bruggenbouwers, shared on LinkedIn: “The…

Oct 20, 2024, 19:52 | Blog

Stephen V Liu: Case report in Annals of Oncology of patients with NUT carcinoma responding to lurbinectedin

Stephen V Liu shared a post on X, about recent case report published in Annals…

Oct 19, 2024, 04:06 | Blog

Amol Akhade: Exciting advancements in cervical cancer treatment with two major breakthroughs over this year

Amol Akhade shared a post on LinkedIn: ''Exciting advancements in cervical cancer treatment with two…

Oct 17, 2024, 04:23 | Blog

Amol Akhade: Interlace trial shows OS benefit for advanced cervical cancer

Amol Akhade shared the following on LinkedIn: “So finally it is published. The much-awaited Interlace…

Oct 15, 2024, 11:55 | Insight

Overall survival with Pembrolizumab in early-stage TNBC - Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X: "Check out this Practice Update commentary from…

Oct 14, 2024, 10:30 | Insight

MHRA Approves Merck and Astellas/Pfizer's Bladder Cancer Combination Therapy

The MHRA has approved the combination of Keytruda (pembrolizumab) and Padcev (enfortumab vedotin) as a…

Oct 12, 2024, 00:33 | Drugs

PD-1 therapy rechallange after adjuvant pembrolizumab in renal cancer - Uromigos

Uromigos shared on X: '' The uromigos Live 2024 meeting asked some questions. Here is…

Oct 10, 2024, 14:16 | Dialogues

NIAGARA Study Insights: Durvalumab and Chemotherapy in Bladder Cancer Treatment | Dr. Petros Grivas

In this episode of OncoDaily, Dr. Petros Grivas joins host Chandler Park to discuss the…

Oct 9, 2024, 23:19 | Insight

Amol Akhade: Pembrolizumab shows EFS Benefit in Perioperative Head Neck SCC

Amol Akhade shared about Pembrolizumab's Benefit in Perioperative Head Neck SCC. Read his post on…

Oct 9, 2024, 14:05 | Insight

Merck's KEYNOTE-689 Trial Achieves Milestone in Head and Neck Cancer Treatment

Merck has announced the Phase 3 KEYNOTE-689 trial for Head and Neck Cancer. Merck has…

Oct 7, 2024, 15:53 | Insight

Pembrolizumab vs. Observation in Muscle-Invasive Urothelial Carcinoma

Tres Uramigas shared on X: “Sure! Here’s the post without the usernames: AMBASSADOR: Phase III…

Oct 5, 2024, 13:07 | Positive

Jimmy Carter at 100: A Legacy of Resilience and the Power of Immunotherapy

Jimmy Carter (James Earl Carter, Jr.), the thirty-ninth president of the United States, was born…

Oct 3, 2024, 13:59 | Dialogues

Advancing Oncology Trials: Innovative Designs and Breakthroughs in Cancer Research

In this engaging talk, the speaker Prof. Richard Sullivan from King's College London shares insights…

Oct 1, 2024, 15:49 | Insight

Shankar Siva: QoL outcomes in the adaptive radiotherapy SPRINT PET trial

Shankar Siva, Radiation Oncologist at the Peter MacCallum Cancer Centre, shared on X: “ASTRO24 -…

Sep 23, 2024, 23:48 | Insight

Adjuvant Pembrolizumab in High-Risk Muscle-Invasive Urothelial Carcinoma summary by Maria Natalia Gandur Quiroga

Maria Natalia Gandur Quiroga shared a post on X: "Adjuvant Pembrolizumab in High-Risk Muscle-Invasive Urothelial Carcinoma…

Sep 23, 2024, 15:50 | Insight

Guru Sonpavde: ESMO24 bladder cancer practice-changing highlight

Guru Sonpavde, Genitourinary Oncology and Phase I Clinical Trials Director of Chair of Bladder Cancer…

Sep 22, 2024, 17:46 | Blog

Francisco J. Esteva: KEYNOTE-522 Trial Shows Pembrolizumab Boosts Survival in Triple-Negative Breast Cancer

Francisco J. Esteva, Chief, Division of Hematology and Medical Oncology at Lenox Hill Hospital, posted the…

Sep 21, 2024, 13:04 | Blog

Guru Sonpavde: Adjuvant pembrolizumab improved outcomes in MIBC

Guru Sonpavde, Genitourinary Oncology and Phase I Clinical Trials Director of Chair of Bladder Cancer…

Sep 19, 2024, 07:37 | Blog

Patrizia Giannatempo: The benefit of adjuvant pembrolizumab with extended follow-up 45 months

Patrizia Giannatempo shared a post on X: "The AMBASSADOR trial confirms the benefit of adjuvant…

Sep 18, 2024, 09:51 | Blog

Sumanta K. Pal: Plenty of terrific microbiome based presentations at ESMO24

Sumanta K. Pal shared a post on X: ''While I've been principally focused on genitourinary…

Sep 18, 2024, 09:18 | Insight

34 Posts Not to Miss From ESMO24 Day 4

The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at…

Sep 17, 2024, 16:37 | Blog

Erika Hamilton: KN522 OS data shows 5% overall survival improvement in TNBC with pembrolizumab

Erika Hamilton posted the following on Twitter: “KN522 OS data 5 years after the initial pCR…

Sep 17, 2024, 16:11 | Blog

Amol Akhade: ESMO Presidential Today - Keynote 522 Shows Overall Survival

Amol Akhade shared a post on LinkedIn: ''ESMO presidential today. Keynote 522 shows overall survival…

Sep 17, 2024, 15:11 | Blog

Toni Choueiri: New standard of care for high-risk locally advanced cervical cancer

Toni Choueiri shared a post on X: ''New standard of care for high-risk locally advanced…

Sep 15, 2024, 15:01 | Insight

MD Anderson Research Highlights Special Edition: ESMO 2024

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent…

Sep 14, 2024, 15:40 | Insight

Key Findings from the PECATI Trial at ESMO 2024

The results of the PECATI trial were recently presented at ESMO 2024. The PECATI trial…

Sep 14, 2024, 12:01 | Blog

Zhen Su: Phase III NSCLC results are out – Ivonescimab vs. Pembrolizumab!

Zhen Su, CEO at Marengo Therapeutics, posted the following on LinkedIn: “Phase III NSCLC Ivonescimab (Anti-VEGF/PD-1…

Sep 13, 2024, 10:46 | Blog

Chris De Savi: Breaking News from WCLC24

Chris De Savi shared a post on LinkedIn: ''Ivonescimab Outshines Keytruda in 1st Line Lung…

Sep 11, 2024, 13:54 | Blog

Noemi Reguart: Presidential Phase 3, Ivonescimab vs Pembrolizumab for PD-L1+ advanced NSCLC

Noemi Reguart shared a post on X: ''WCLC24 Presidential. Phase 3 Ivonescimab (AK112) versus Pembrolizumab…

Sep 10, 2024, 13:45 | Societies

Rami Manochakian's key highlights from WCLC24

WCLC is a major international event focused on the latest advancements in lung cancer research,…

Sep 9, 2024, 14:16 | Blog

Tom Powles: Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions

Tom Powles shared a post on X, about recent paper published in ESMO Open: The…